ES2120477T3 - Administracion iontoforetica de medicamentos perfeccionada. - Google Patents

Administracion iontoforetica de medicamentos perfeccionada.

Info

Publication number
ES2120477T3
ES2120477T3 ES93300198T ES93300198T ES2120477T3 ES 2120477 T3 ES2120477 T3 ES 2120477T3 ES 93300198 T ES93300198 T ES 93300198T ES 93300198 T ES93300198 T ES 93300198T ES 2120477 T3 ES2120477 T3 ES 2120477T3
Authority
ES
Spain
Prior art keywords
morpholine
alkyl
lipid modifier
water
iontophoresis
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES93300198T
Other languages
English (en)
Inventor
Carlos M Samour
Solomon R Eisenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston University
Macrochem Corp
Original Assignee
Boston University
Macrochem Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston University, Macrochem Corp filed Critical Boston University
Application granted granted Critical
Publication of ES2120477T3 publication Critical patent/ES2120477T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/02—Cosmetics or similar toiletry preparations characterised by special physical form
    • A61K8/0208—Tissues; Wipes; Patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4906—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom
    • A61K8/4913—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with one nitrogen as the only hetero atom having five membered rings, e.g. pyrrolidone carboxylic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K8/00—Cosmetics or similar toiletry preparations
    • A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
    • A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
    • A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
    • A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
    • A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
    • A61Q19/00—Preparations for care of the skin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
    • A61K2800/80—Process related aspects concerning the preparation of the cosmetic composition or the storage or application thereof
    • A61K2800/83—Electrophoresis; Electrodes; Electrolytic phenomena

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Birds (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dermatology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Electrotherapy Devices (AREA)

Abstract

SE PRESENTA UN METODO NUEVO Y MEJORADO PARA LA ADMINISTRACION TRANSDERMICA DE AGENTES MEDIANTE LA UTILIZACION DE UNA IONTOFORESIS JUNTO CON UN MODIFICADOR LIPIDO DE CORNEO DE ESTRATO. EL MODIFICADOR LIPIDOS SE PUEDE UTILIZAR ANTES DE LA IONTOFORESIS O AL MISMO TIEMPO. LA MODIFICADOR LIPIDO SE PUEDE SELECCIONAR DE UNA GRAN VARIEDAD DE UNIDADES DE LA FORMULA GENERAL R-X EN DONDE R ES UN ALQUILO C6 A C28 O UN ALQUILO INSATURADO O X ES UN MIEMBRO DE ENTRE LOS SIGUIENTES: 1,3DIOXANO; 1,3-DIOXOLANO; LACTAMA; MORFOLINA; -COOH; -OH; -COOR''; C-N(R'')2; CARBONATOS DE PROPILENO O CICLOETILENO; -CONH2; -(CH2CH2O)NH; ACETALES Y SEMIACETALES; Y EN DONDE R1 ES ALQUILO INFERIOR (EJ. DE C1 A C3) Y N ES UN ENTERO DE 1 A 20. OPCIONALMENTE, SE PUEDE ENCONTRAR PRESENTE UN COMPUESTO QUIMICO SOLUBLE EN AGUA, POLAR DEL GRUPO DE ALCOHOLES, GLICOLES, LACTAMAS, DIOXOLANOS, ESTERES, UREAS, MORFOLINA Y SIMILARES. TAMBIEN SE PRESENTAN LAS COMPOSICIONES Y LOS ARTICULOS UTILES PARA EL PROCESO DE LA PRESENTE INVENCION.
ES93300198T 1992-01-21 1993-01-13 Administracion iontoforetica de medicamentos perfeccionada. Expired - Lifetime ES2120477T3 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US82338092A 1992-01-21 1992-01-21

Publications (1)

Publication Number Publication Date
ES2120477T3 true ES2120477T3 (es) 1998-11-01

Family

ID=25238587

Family Applications (1)

Application Number Title Priority Date Filing Date
ES93300198T Expired - Lifetime ES2120477T3 (es) 1992-01-21 1993-01-13 Administracion iontoforetica de medicamentos perfeccionada.

Country Status (7)

Country Link
US (1) US5527797A (es)
EP (1) EP0552879B1 (es)
JP (1) JPH05339170A (es)
AT (1) ATE169826T1 (es)
CA (1) CA2087679C (es)
DE (1) DE69320378T2 (es)
ES (1) ES2120477T3 (es)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996002232A1 (en) * 1994-07-13 1996-02-01 Alza Corporation Composition and method for enhancing transdermal electrotransport agent delivery
US5736580A (en) * 1994-11-14 1998-04-07 Alza Croporation Composition, device, and method for electrotransport agent delivery
US5861439A (en) * 1994-11-14 1999-01-19 Alza Corporation Method for enhanced electrotransport agent delivery
US5620980A (en) * 1995-02-22 1997-04-15 Macrochem Corporation Method for treating hair loss
US5985316A (en) * 1995-04-28 1999-11-16 Alza Corporation Composition and method of enhancing electrotransport agent delivery
US5990179A (en) * 1995-04-28 1999-11-23 Alza Corporation Composition and method of enhancing electrotransport agent delivery
ATE255450T1 (de) * 1995-06-09 2003-12-15 Hisamitsu Pharmaceutical Co Matrix für iontophorese
DE19610396C2 (de) * 1996-03-16 1998-11-26 Krewel Meuselbach Gmbh Dimethylsulfoxid-haltige topische Zubereitung
US5908400A (en) * 1996-06-20 1999-06-01 Hisamitsu Pharmaceutical Co., Inc. Device structure for iontophoresis
US7629384B2 (en) * 1997-09-17 2009-12-08 Strategic Science & Technologies, Llc Topical delivery of L-arginine to cause beneficial effects
US7914814B2 (en) * 1997-09-17 2011-03-29 Strategic Science & Technologies, Llc Topical delivery of arginine of cause beneficial effects
EP1030688B1 (en) * 1997-11-12 2004-09-29 Alza Corporation Method for dermally administering polypeptides
US20050203187A1 (en) * 1998-06-01 2005-09-15 Verbiscar Anthony J. Formulations useful for the treatment of varicella zoster virus infections and methods for the use thereof
US5942545A (en) * 1998-06-15 1999-08-24 Macrochem Corporation Composition and method for treating penile erectile dysfunction
US6475514B1 (en) * 1998-12-03 2002-11-05 Andrew Blitzer Athletic patch
US7137975B2 (en) * 2001-02-13 2006-11-21 Aciont, Inc. Method for increasing the battery life of an alternating current iontophoresis device using a barrier-modifying agent
WO2002081024A1 (en) * 2001-04-04 2002-10-17 Alza Corporation Transdermal electrotransport delivery device including an antimicrobial compatible reservoir composition
WO2003090855A1 (fr) * 2002-04-25 2003-11-06 Centre Pharmapeptides Appareil et ensemble pour l'administration d'un agent antimicrobien
CA2500713C (en) * 2002-10-04 2012-07-03 Photokinetix, Inc. Photokinetic delivery of biologically active substances using pulsed incoherent light
DE10314976A1 (de) * 2003-04-02 2004-10-14 Bayer Healthcare Ag Verbesserte Penetration von Wirkstoffen in Zellen und Organe
EP1732577B1 (en) * 2004-02-23 2013-04-10 Strategic Science & Technologies, LLC Topical delivery of l-arginine to improve body and skin appearance
US20050220439A1 (en) * 2004-03-19 2005-10-06 Carton Owen A Interactive multimedia system and method
CA2563678A1 (en) * 2004-04-19 2005-11-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US9226909B2 (en) 2004-04-19 2016-01-05 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US20110028548A1 (en) * 2004-04-19 2011-02-03 Strategic Science & Technologies, Llc Beneficial effects of increasing local blood flow
US8165668B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc Method for magnetic modulation of neural conduction
US8180446B2 (en) * 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method and system for cyclical neural modulation based on activity state
US8165669B2 (en) * 2007-12-05 2012-04-24 The Invention Science Fund I, Llc System for magnetic modulation of neural conduction
US8170659B2 (en) * 2007-12-05 2012-05-01 The Invention Science Fund I, Llc Method for thermal modulation of neural activity
US8180447B2 (en) 2007-12-05 2012-05-15 The Invention Science Fund I, Llc Method for reversible chemical modulation of neural activity
US8195287B2 (en) * 2007-12-05 2012-06-05 The Invention Science Fund I, Llc Method for electrical modulation of neural conduction
US8989858B2 (en) 2007-12-05 2015-03-24 The Invention Science Fund I, Llc Implant system for chemical modulation of neural activity
US20090149797A1 (en) * 2007-12-05 2009-06-11 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System for reversible chemical modulation of neural activity
US8170658B2 (en) 2007-12-05 2012-05-01 The Invention Science Fund I, Llc System for electrical modulation of neural conduction
US20100022497A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method for treating or preventing a cardiovascular disease or condition utilizing estrogen receptor modulators based on APOE allelic profile of a mammalian subject
US20100022991A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware System and device for maintaining physiological levels of steroid hormone in a subject
US20100022494A1 (en) * 2008-07-24 2010-01-28 Searete Llc, A Limited Liability Corporation Of The State Of Delaware Method, device, and kit for maintaining physiological levels of steroid hormone in a subject
MX337166B (es) 2009-06-24 2016-02-15 Composicion topica que contiene ibuoprofeno.
US11684624B2 (en) 2009-06-24 2023-06-27 Strategic Science & Technologies, Llc Treatment of erectile dysfunction and other indications
WO2010151241A1 (en) 2009-06-24 2010-12-29 Strategic Science & Technologies, Llc Topical composition containing naproxen
US20110183963A1 (en) * 2009-12-31 2011-07-28 Travis Mickle Amino Acid Conjugates of Quetiapine, Process for Making and Using the Same
WO2011112657A1 (en) 2010-03-11 2011-09-15 Kempharm, Inc. Fatty acid conjugates of quetiapine, process for making and using the same
CN105920603B (zh) 2010-12-29 2022-02-11 战略科学与技术有限责任公司 勃起功能障碍和其它适应症的治疗
US9289495B2 (en) 2010-12-29 2016-03-22 Strategic Science & Technologies, Llc Systems and methods for treatment of allergies and other indications

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4861764A (en) * 1986-11-17 1989-08-29 Macro Chem. Corp. Percutaneous absorption enhancers, compositions containing same and method of use
ES2095929T3 (es) * 1989-10-23 1997-03-01 Theratech Inc Dispositivo iontoforetico que emplea un regulador del regimen.
US5023085A (en) * 1989-11-29 1991-06-11 Pfizer Inc. Transdermal flux enhancers in combination with iontophoresis in topical administration of pharmaceuticals
US5167616A (en) * 1989-12-14 1992-12-01 Alza Corporation Iontophoretic delivery method
AU664178B2 (en) * 1991-03-19 1995-11-09 Vithal J. Rajadhyaksha Compositions and method comprising aminoalcohol derivatives as membrane penetration enhancers
US5131403A (en) * 1991-06-05 1992-07-21 Becton Dickinson And Company Method for obtaining blood using iontophoresis

Also Published As

Publication number Publication date
CA2087679A1 (en) 1993-07-22
EP0552879B1 (en) 1998-08-19
EP0552879A1 (en) 1993-07-28
US5527797A (en) 1996-06-18
CA2087679C (en) 2004-08-17
ATE169826T1 (de) 1998-09-15
DE69320378T2 (de) 1999-04-29
JPH05339170A (ja) 1993-12-21
DE69320378D1 (de) 1998-09-24

Similar Documents

Publication Publication Date Title
ES2120477T3 (es) Administracion iontoforetica de medicamentos perfeccionada.
FI914961A0 (fi) Peptidfoereningar, foerfarande foer deras framstaellning och dessa innehaollande farmaceutisk blandning.
HUT67285A (en) Cyclic ureas and analogues and pharmaceutical compositions
NO913750L (no) Fremgangsmaate for fremstilling av terapeutisk aktive heterocykliske derivater.
DE69425162T2 (de) 4,5-diaryloxazol-derivate
ATE172731T1 (de) Pyrazolopyridinverbindung und verfahren zu ihrer herstellung
EP1312601A4 (en) CARBOXYLENE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND MEDICAMENTS CONTAINING THEM AS AN ACTIVE SUBSTANCE
ES2057016T3 (es) Compuestos de acido 3-pirrolidiniltio-1-azabiciclo (3.2.0) hept-2-eno-2-carboxilico.
WO2003059880A1 (fr) Derive d'amino-alcool ou derive d'acide phosphonique et composition medicamenteuse les contenant
KR910009712A (ko) 세펨 화합물 및 이의 제조방법
DE68926981D1 (de) Cephemverbindungen und Verfahren zu ihrer Herstellung
ATE122669T1 (de) Zearalanol-derivate mit anabolytischer wirkung.
ZA907736B (en) Derivatives of pyridone,process and intermediates of preparation,their application as medicaments and compositions containing them
EP0414903A4 (en) New thioproline derivative
RU94018706A (ru) Циклические соединения мочевины, пригодные для использования, в качестве антиаритмических и антифибриллярных средств, фармацевтические композиции на их основе, способ лечения
RU94016524A (ru) Циклические уретаны, пригодные в качестве средств против аритмии и фибриляции, способ лечения, фармацевтическая композиция
IL141114A0 (en) NOVEL C-2 S/O- AND S/N FORMALDEHYDE ACETAL DERIVATIVES OF CARBAPENEM-3-CARBOXYLIC ACIDS AND THEIR USE AS ANTIBIOTICS AND β-LACTAMASE INHIBITORS
ATE131480T1 (de) Pyrimidoindolderivate und verfahren zu ihrer herstellung
ATE228359T1 (de) Hemmung der leukotrienbiosynthese mittels harnstoffderivaten
RU2002126568A (ru) Средство для лечения заболевания, обусловленного стенозирующим поражением сосудов
RU2001130750A (ru) Замещенные триптофансодержащие дипептиды с холецистокининонегативной или холецистокининопозитивной активностью
TW360630B (en) A secoaporphine compounds on arrhythmia
TH13800A (th) อนุพันธ์ชนิดใหม่ของเพพไทด์
TH16620A (th) " สารยับยั้ง hiv โปรตีเอสที่มีประโยชน์สำหรับบำบัดรักษาโรคเอดส์ "

Legal Events

Date Code Title Description
FG2A Definitive protection

Ref document number: 552879

Country of ref document: ES